Last reviewed · How we verify
Liraglutide Pen Injector
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying.
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying. Used for Type 2 diabetes mellitus, Weight management in obese or overweight patients.
At a glance
| Generic name | Liraglutide Pen Injector |
|---|---|
| Also known as | Victoza, Saxenda, Liraglutide, Placebo Saxenda, Placebo liraglutide 3 mg |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Liraglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also reduces glucagon secretion when blood glucose is elevated and delays gastric emptying, leading to reduced postprandial glucose excursions. These combined effects improve glycemic control and promote weight loss in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
- Weight management in obese or overweight patients
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Hypoglycemia
- Headache
Key clinical trials
- The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes (PHASE2)
- Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues (EARLY_PHASE1)
- Liraglutide Effects on Epicardial Fat Inflammatory Genes (PHASE4)
- Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated) (PHASE2)
- Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists (NA)
- Use of a GLP-1R Agonist to Treat Opioid Use Disorder (PHASE1, PHASE2)
- Efficacy of Liraglutide Therapy in Patients With IPAA (PHASE2)
- Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liraglutide Pen Injector CI brief — competitive landscape report
- Liraglutide Pen Injector updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI